Aclaris Therapeutics, Inc.
ACRS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $3,299 | $1,777 | $1,455 | $9,211 |
| % Growth | 85.6% | 22.1% | -84.2% | – |
| Cost of Goods Sold | $538 | $1,850 | $506 | $9,301 |
| Gross Profit | $2,761 | -$73 | $949 | -$90 |
| % Margin | 83.7% | -4.1% | 65.2% | -1% |
| R&D Expenses | $13,028 | $11,449 | $11,584 | $9,026 |
| G&A Expenses | $4,871 | $5,386 | $6,139 | $4,954 |
| SG&A Expenses | $4,871 | $5,386 | $6,139 | $4,954 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $2,011 | $1,500 | $1,310 | $85,605 |
| Operating Expenses | $19,910 | $18,335 | $19,033 | $99,585 |
| Operating Income | -$17,149 | -$18,408 | -$18,084 | -$99,675 |
| % Margin | -519.8% | -1,035.9% | -1,242.9% | -1,082.1% |
| Other Income/Exp. Net | $2,535 | $2,979 | $2,999 | $3,123 |
| Pre-Tax Income | -$14,614 | -$15,429 | -$15,085 | -$96,552 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$14,614 | -$15,429 | -$15,085 | -$96,552 |
| % Margin | -443% | -868.3% | -1,036.8% | -1,048.2% |
| EPS | -0.12 | -0.13 | -0.12 | -1.01 |
| % Growth | 7.7% | -8.3% | 88.1% | – |
| EPS Diluted | -0.12 | -0.13 | -0.12 | -1.01 |
| Weighted Avg Shares Out | 122,619 | 122,581 | 122,390 | 95,306 |
| Weighted Avg Shares Out Dil | 122,619 | 122,581 | 122,390 | 95,306 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,819 | $2,018 | $2,166 | $2,103 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $210 | $114 | $128 | $143 |
| EBITDA | -$14,404 | -$16,794 | -$17,656 | -$13,927 |
| % Margin | -436.6% | -945.1% | -1,213.5% | -151.2% |